- Home
- ALV vs MRNA Comparison
ALV vs MRNA Comparison
Compare ALV & MRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ALV | MRNA |
|---|---|---|
| Founded | 1953 | 2010 |
| Country | Sweden | United States |
| Employees | N/A | N/A |
| Industry | Auto Parts:O.E.M. | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.7B | 11.5B |
| IPO Year | 1997 | 2018 |
Fundamental Metrics
Financial Performance| Metric | ALV | MRNA |
|---|---|---|
| Price | $124.47 | $33.97 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 11 | 13 |
| Target Price | ★ $133.45 | $32.75 |
| AVG Volume (30 Days) | 486.0K | ★ 10.6M |
| Earning Date | 01-30-2026 | 02-13-2026 |
| Dividend Yield | ★ 2.72% | N/A |
| EPS Growth | ★ 25.57 | N/A |
| EPS | ★ 9.69 | N/A |
| Revenue | ★ $10,614,000,000.00 | $2,232,000,000.00 |
| Revenue This Year | $4.71 | N/A |
| Revenue Next Year | $4.08 | $2.17 |
| P/E Ratio | $12.91 | ★ N/A |
| Revenue Growth | ★ 0.85 | N/A |
| 52 Week Low | $75.49 | $22.28 |
| 52 Week High | $129.54 | $45.40 |
Technical Indicators
Market Signals| Indicator | ALV | MRNA |
|---|---|---|
| Relative Strength Index (RSI) | 61.70 | 61.46 |
| Support Level | $121.59 | $33.72 |
| Resistance Level | $125.52 | $37.10 |
| Average True Range (ATR) | 1.87 | 1.88 |
| MACD | 0.42 | 0.14 |
| Stochastic Oscillator | 86.25 | 62.94 |
Price Performance
Historical ComparisonAbout ALV Autoliv Inc.
Autoliv Inc is the world-wide leader in passive safety components and systems for the auto industry. Products include seat belts, frontal air bags, side-impact air bags, air bag inflators, and steering wheels. The Renault-Nissan-Mitsubishi alliance is the company's largest customer at 10% of 2023 revenue, with Stellantis accounting for 10% and Volkswagen 9%. At 34% of 2023 revenue, the Americas was Autoliv's largest geographic region, followed by Europe at 27%, China at 20%, and rest of world at 19%.
About MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.